Compounds, compositions and methods for the treatment of poxvirus infections
    4.
    发明授权
    Compounds, compositions and methods for the treatment of poxvirus infections 有权
    用于治疗痘病毒感染的化合物,组合物和方法

    公开(公告)号:US08642577B2

    公开(公告)日:2014-02-04

    申请号:US11401805

    申请日:2006-04-10

    IPC分类号: A61K31/675 A61K31/40

    摘要: The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or a salt, ester, or prodrug thereof in combination or alternation with at least a second anti-poxvirus agent. The second anti-poxvirus agent is, for example, a biologic, such as a pegylated interferon.

    摘要翻译: 本申请提供了用于治疗痘病毒感染(例如正痘病毒感染)的抗病毒化合物联合治疗的方法和组合物。 在一个实施方案中,提供了治疗痘病毒感染的方法,其包括向有需要的宿主施用西多福韦,环西非多韦或其盐,酯或前药与至少第二种抗痘病毒剂组合或替代 。 第二种抗痘病毒剂是例如生物制剂,例如聚乙二醇化干扰素。

    METHODS OF TREATING VIRAL INFECTIONS
    7.
    发明申请
    METHODS OF TREATING VIRAL INFECTIONS 有权
    治疗病毒感染的方法

    公开(公告)号:US20110021464A1

    公开(公告)日:2011-01-27

    申请号:US12864431

    申请日:2009-01-23

    IPC分类号: A61K31/675 A61P31/12

    摘要: The present invention provides methods of treating human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, including administering a compound described in the invention in an amount effective treat the HIV and/or HBV infection and at least substantially inhibit the development of resistance to said antiviral compounds in the subject. Pharmaceutical compositions are also provided.

    摘要翻译: 本发明提供了治疗人类免疫缺陷病毒(HIV)和/或乙型肝炎病毒(HBV)感染的方法,包括以有效治疗HIV和/或HBV感染的量施用本发明中描述的化合物,并至少基本上抑制 发展对受试者中所述抗病毒化合物的抗性。 还提供药物组合物。

    Compounds, compositions and methods for treating ocular conditions
    8.
    发明授权
    Compounds, compositions and methods for treating ocular conditions 有权
    用于治疗眼部病症的化合物,组合物和方法

    公开(公告)号:US08614200B2

    公开(公告)日:2013-12-24

    申请号:US13386604

    申请日:2010-07-21

    IPC分类号: A61K31/675

    摘要: The present invention provides methods of treating viral infection of the eye or posterior ocular condition including administering a pharmaceutical composition comprising a compound described in the present application. In some embodiments, the pharmaceutical composition is topically administered. In another embodiment, the pharmaceutical composition is orally administered or intraocularly administered.

    摘要翻译: 本发明提供了治疗眼睛或后眼症状的病毒感染的方法,包括施用包含本申请中描述的化合物的药物组合物。 在一些实施方案中,局部施用药物组合物。 在另一个实施方案中,药物组合物经口给药或眼内施用。

    Methods to manufacture 1,3-dioxolane nucleosides
    9.
    发明授权
    Methods to manufacture 1,3-dioxolane nucleosides 有权
    1,3-二氧戊环核苷的制备方法

    公开(公告)号:US08420354B2

    公开(公告)日:2013-04-16

    申请号:US12870319

    申请日:2010-08-27

    摘要: This application provides a process for preparing enantiomerically pure β-D-dioxolane nucleosides. In particular, a new synthesis of (−)-DAPD, suitable for large scale development, is described. In one embodiment the invention provides a process for preparing a substantially pure β-D- or β-L-1,3-dioxolane nucleosides comprising a) preparing or obtaining an esterified 2,2-dialkoxy ethanol; b) cyclizing the esterified 2,2-dialkoxy ethanol with glycolic acid to obtain a 1,3-dioxolane lactone; c) resolving the 1,3-dioxolane lactone to obtain a substantially pure D- or L-lactone; d) selectively reducing and activating the D- or L-chiral lactone to obtain a substantially pure D- or L-1,3-dioxolane; e) coupling the D- or L-1,3-dioxolane to an activated and/or protected purine or pyrimidine base; and f) optionally purifying the nucleoside to obtain a substantially pure protected β-D- or β-L-1,3-dioxolane nucleoside.

    摘要翻译: 本申请提供了制备对映异构体纯的对二氧戊环核苷的方法。 特别地,描述了适用于大规模开发的( - ) - DAPD的新合成。 在一个实施方案中,本发明提供了制备基本上纯的二 - 或 - bgr--L-1,3-二氧戊环核苷的方法,其包括a)制备或获得酯化的2,2-二烷氧基乙醇; b)用乙醇酸环化酯化的2,2-二烷氧基乙醇得到1,3-二氧戊环内酯; c)拆分1,3-二氧戊环内酯以获得基本上纯的D-或L-内酯; d)选择性还原和活化D-或L-手性内酯,得到基本上纯的D-或L-1,3-二氧戊环; e)将D-或L-1,3-二氧戊环与活化和/或受保护的嘌呤或嘧啶碱基偶联; 和f)任选地纯化所述核苷以获得基本上纯的保护的-β-或 - bgr; -L-1,3-二氧戊环核苷。